



**Maidstone and
Tunbridge Wells**
NHS Trust

Ref: FOI/GS/ID 6939

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

08 October 2021

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to biologic and biosimilar products within Rheumatology.

You asked:

Q1. Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

- a. Abatacept [Orencia]*
- b. Adalimumab [Humira]*
- c. Adalimumab Biosimilars*
- d. Apremilast [Otezla]*
- e. Baricitinib [Olumiant]*
- f. Certolizumab [Cimzia]*
- g. Etanercept [Enbrel]*
- h. Etanercept Biosimilars*
- i. Filgotinib [Jyseleca]*
- j. Golimumab [Simponi]*
- k. Guselkumab [Tremfya]*
- l. Infliximab [Remicade]*
- m. Infliximab Biosimilars*
- n. Ixekizumab [Taltz]*
- o. Risankizumab [Skyrizi]*
- p. Rituximab [MabThera]*
- q. Rituximab Biosimilars*
- r. Sarilumab [Kevzara]*
- s. Secukinumab [Cosentyx]*
- t. Tocilizumab [Ro Actemra]*
- u. Tofacitinib [Xeljanz]*
- v. Upadacitinib [Rinvoq]*

w. Ustekinumab [Stelara]

Q2. Could you please provide the numbers of patients treated for Psoriatic Arthritis ONLY in the last 3 months with the following drugs.

a. Abatacept [Orencia]

b. Adalimumab [Humira]

c. Adalimumab Biosimilars

d. Apremilast [Otezla]

e. Certolizumab [Cimzia]

f. Etanercept [Enbrel]

g. Etanercept Biosimilars

h. Golimumab [Simponi]

i. Guselkumab [Tremfya]

j. Infliximab [Remicade]

k. Infliximab Biosimilars

l. Ixekizumab [Taltz]

m. Risankizumab [Skyrizi]

n. Secukinumab [Cosentyx]

o. Tofacitinib [Xeljanz]

p. Upadacitinib [Rinvoq]

q. Ustekinumab [Stelara]

Trust response:

Q1.

a. 65

b. 98

c. 193

d. 1

e. 12

f. 30

g. 26

h. 192

i. not used

j. 96

k. not used

l. 12

m. 30

n. 1

o. not used

p. 7

q. 46

r. 1

s. 68

t. 27

u. 20

v. 3

w. 5

Q2.

a. 0

b. 23

c. 56

- d. 1
- e. 10
- f. 9
- g. 38
- h. 44
- i. not used
- j. 2
- k. 5
- l. 1
- m. not used
- n. 40
- o. 3
- p. 1
- q. 5